Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5149MR)

This product GTTS-WQ5149MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5149MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5665MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ11025MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ12599MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ8510MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ12869MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ5372MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ7984MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ7201MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.